Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

PubMed 2026 Open access

Read full text
Authors: Bradley Rockwell, Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, Yogen Saunthararajah, Kira Gritsman, Alejandro R. Sica, Noah Saul Kornblum, Nishi Shah, David Levitz, Lauren C. Shapiro, Ridhi Gupta
+9 more Anne Munoz, Aradhika Dhawan, Karen Fehn, Monica Comas, Jhannine Alyssa Verceles, DENNIS L. COOPER, Marina Konopleva, Eric Jay Feldman, Amit Verma
DOI: 10.3324/haematol.2024.287253
Cited by: 0

Fields of Study & Subjects

Acute Myeloid Leukemia Research Glioma Diagnosis and Treatment Histone Deacetylase Inhibitors Research

Publication details

Journal / source
PubMed
Publisher
Ferrata Storti Foundation (Haematologica)
Volume
111
Issue
1
Pages
350–354
Publication date
1 January 2026
Language
EN